United States Patent 8,334,281 (Metoclopramide Nasal Citrate/BAK Clarity)
US Drug Patent: 8,334,281
Core claim package (composition + method): intranasal metoclopramide formulation defined by (i) citrate buffer (ii) benzalkonium chloride (BAK) (iii) tight physicochemical stability targets (clarity vs USP <631> after elevated storage), (iv) citrate concentration (>= 10 mM) and (v) pH/osmolality windows.
What do the independent claims actually require? (Claims 1 and 17)
The patent has two main composition claim centers: Claim 1 (citrate buffer specified) and Claim 17 (adds a benzyl alcohol exclusion/limit). Both are framed around nasal solution clarity after stress storage using USP <631> visual standard.
Claim 1 (broadest citrate-based clarity framework)
A nasal solution comprising:
- Metoclopramide (or a pharmaceutically acceptable salt)
- Citrate buffer
- Benzalkonium chloride
With all of the following limitations:
- Clarity requirement: “clear to pale yellow” compared to standard E, USP <631> after 40°C storage for at least about 4 weeks.
- Citrate concentration: citrate concentration >= about 10 mM, where citrate concentration is defined as
[citrate]=[citric acid]+[dihydrogen citrate ion]+[hydrogen citrate ion]+[citrate ion].
- Nasal solution context is explicit.
Claim 17 (same clarity framework, tighter preservative system)
A nasal solution comprising:
- Metoclopramide (or a pharmaceutically acceptable salt)
- Citrate buffer
- Benzalkonium chloride
- Less than about 1% w/v benzyl alcohol
And then the same two key stability anchors:
- Clarity vs USP <631> standard E after 40°C for at least about 4 weeks
- Citrate concentration >= about 10 mM
Claim 17 is narrower than Claim 1 by introducing the benzyl alcohol cap.
Business implication: In infringement or freedom-to-operate (FTO) terms, the patent is not just “metoclopramide nasal + citrate + BAK.” It is metoclopramide nasal with citrate >= 10 mM and passes a specific accelerated visual stability screen (USP <631> E benchmark).
How do dependent claims narrow the composition space?
The dependent claims operationalize stability and formulation knobs that likely correspond to actual development learnings (color/clarity driven by pH, citrate level, preservative blend, and solute strength).
pH windows
- Claim 2: starting pH >= 4.5
- Claim 3: starting pH >= 5.0
- Claim 10: starting pH > 4.5 (buffer + BAK + clarity framework version without explicit citrate-only language in the preamble)
- Claim 11: starting pH >= 4.6
- Claim 12: ties the “claim 10” framework to the 8-week stability endpoint
- Claim 20: starting pH >= 4.5
- Claim 21: starting pH >= 5.0
Interpretation of scope: The patent does not require a single pH number, but forces lower bounds that reduce risk of instability under acid stress.
Extended stability endpoint
- Claim 9: “clear to pale yellow” after 40°C for at least about 8 weeks (Claim 1 anchor)
- Claim 12: same 8-week endpoint tied to Claim 10
- Claim 19: same 8-week endpoint tied to Claim 17
Interpretation of scope: The 8-week language creates a second commercial design target. If a product only meets 4 weeks but fails at 8 weeks, it may avoid these dependent claim scopes.
Antioxidant exclusion (negative limitation)
- Claim 4: “substantially free of any additional antioxidant”
- Claim 22: same concept in the Claim 17 line
Interpretation of scope: The phrase is open-textured (“substantially free”), but it functions as a deterrent against packaging metoclopramide with standard antioxidant stabilization strategies (depending on how “additional antioxidant” is defined or argued).
Optional excipients (non-limiting examples but still claim features)
Both claim lines allow a list of additional components if the core constraints remain:
- Claim 5 / Claim 23: may further comprise at least one member of:
- salt
- EDTA
- sorbitol
- sugar (including reduced sugar such as sorbitol)
- flavoring agent
Interpretation of scope: These are permissive “at least one member” examples, not a closed set. The patent still requires citrate >= 10 mM and the clarity/BAK constraints.
Metoclopramide concentration window
- Claim 6 / Claim 24: 20.0% (w/v) to 30.0% (w/v) metoclopramide (or salt)
Benzalkonium chloride concentration window
- Claim 7 / Claim 25: 0.005% (w/v) to 0.05% (w/v) BAK
Osmolality window
- Claim 8 / Claim 26: 500 to 1400 mOsm/kg
These three quantitative windows (metoclopramide %, BAK %, osmolality) are where product designs typically land to meet nasal tolerability and preservative effectiveness.
What buffers are inside or outside the claimed landscape?
The patent has an important structural quirk: Claim 1 and Claim 17 clearly require a citrate buffer, but Claim 13 contains a very broad buffer selection list.
Claim 13 (buffer selection list)
Claim 13: “buffer is selected from” a long group of buffer systems including:
- citrate
- phosphate-related systems (citric acid/phosphate, phosphate, citrate-phosphate-borate)
- acetate, succinate, maleate
- borate, cacodylate, veronal acetate, barbital, veronal (Teorell-Stanhagen appears as “citrate-phosphate-borate”)
- common biological buffers (HEPES, MES, MOPS, PIPES, HEPES, etc.)
- many other sulfonates/amino acid buffers
- TEA / triethanolamine-containing systems
Scope effect: The dependent buffer selection list is broad. In practice, it may broaden the claim set beyond citrate-only systems depending on how the claim is construed with the earlier limitations. But the core claim requirement remains: the composition must satisfy the “clear to pale yellow vs USP <631> after 40°C storage” and citrate concentration language tied to Claim 1/17 wording.
Claim interaction: Claim 13 is dependent on Claim 1 (“The pharmaceutical composition of claim 1, having a starting pH… and wherein buffer is selected…”). Because Claim 1 already requires a citrate buffer and citrate concentration >= 10 mM, Claim 13’s buffer list likely addresses how the citrate buffer can be constituted or what buffer combinations are acceptable while still meeting the citrate-dependent concentration metric.
Method claims: what conduct is covered? (Claims 14–16 and 27–29)
The patent also covers therapeutic use by intranasal administration of the claimed compositions.
Treatment method
- Claim 14: method of treating a patient using an intranasal effective amount of Claim 1 composition
- Claim 15: disorder treatable with metoclopramide
- Claim 16: disorders listed:
- gastroparesis
- emesis
- delayed emesis
- nausea
Parallel treatment method for the benzyl alcohol constrained composition
- Claim 27: method of treating using intranasal effective amount of Claim 17 composition
- Claim 28 / Claim 29: same disorder set (gastroparesis, emesis, delayed emesis, nausea)
Scope effect: Any intranasal metoclopramide product that meets Claim 1 or Claim 17 formulation constraints could implicate the method claims when used to treat those indications.
What is the claim “center of gravity” for infringement risk?
A product that matches the following tuple is at highest risk:
- Route: intranasal solution
- Drug: metoclopramide (salt allowed)
- Preservative: benzalkonium chloride within 0.005% to 0.05% w/v
- Buffer system: citrate buffer with citrate concentration >= 10 mM
- Stability/appearance: remains “clear to pale yellow” vs standard E USP <631> after 40°C for at least 4 weeks (and possibly 8 weeks)
- pH: starting pH >= 4.5 (and in some dependent scopes >= 5.0)
- Optionals: substantially free of additional antioxidant (for Claim 4/22)
- Compositional design (dependent risk):
- metoclopramide 20 to 30% w/v
- osmolality 500 to 1400 mOsm/kg
- benzyl alcohol < 1% w/v (for Claim 17 and its method claims)
Lowest-risk design patterns (conceptual, based on claim language): use a different buffer without citrate concentration >= 10 mM, remove/alter BAK, or design to fail the USP <631> E clarity benchmark at 40°C storage. Also, exceed benzyl alcohol > 1% w/v to avoid Claim 17, if otherwise compatible with nasal formulation constraints.
Patent landscape (U.S.) for 8,334,281: what can be stated from the claim set alone
The information supplied includes only the claims. From those claims, the landscape can be characterized at the technical scope level, but not the legal landscape level (other patents’ numbers, assignees, priority dates, expiration, continuations, or litigation history). Therefore, the landscape below is a scope map of where competitors would typically be positioned relative to this patent.
1) Direct formulation design “lanes”
Competitors in metoclopramide nasal products generally align to one of these lanes:
-
Lane A (closest): citrate buffer with citrate >=10 mM + BAK within 0.005–0.05% + meets USP <631> clarity after 40°C 4+ weeks
Matches Claim 1 and can match Claim 17 unless benzyl alcohol is present above 1% or other constraints diverge.
-
Lane B (preservative divergence): replace BAK (or run BAK outside 0.005–0.05%)
May avoid Claim 1/17 dependent coverage if BAK is not present as claimed.
-
Lane C (citrate divergence): reduce citrate below 10 mM or switch buffer system while avoiding citrate concentration definition
May avoid Claim 1/17 core citrate concentration limitation.
-
Lane D (clarity divergence): formulations that do not maintain “clear to pale yellow” vs USP <631> standard E after the specified stress storage
May avoid the appearance-based claim limitations.
-
Lane E (benzyl alcohol divergence): benzyl alcohol at or above 1% w/v
Targets avoidance of Claim 17/27/29, while Claim 1 could still be implicated if other requirements match.
2) Clearance vs USP <631> as the discriminator
The patent’s core differentiation is a visual stability spec tied to:
- comparison category: “standard E” (USP <631>)
- acceptance: “clear to pale yellow”
- storage: 40°C
- time: 4 weeks in core claim language; 8 weeks in dependent claims
That makes the patent less about conventional “buffer + preservative” recipes and more about a stability window that is measurable in finished dosage.
Scope control: how claim construction typically narrows actual products
The claim language creates multiple conjunctive conditions. For a competitor product to fall inside:
- Every required element must be present (metoclopramide + citrate concentration >=10 mM + BAK + nasal clarity spec + storage spec).
- Dependent quantitative windows (metoclopramide %, BAK %, osmolality, pH thresholds, benzyl alcohol limit) add extra filters.
Practical takeaway for portfolio strategy: even small reformulation changes around citrate concentration, BAK presence, pH lower bounds, or benzyl alcohol content can move a product outside dependent claim coverage, and potentially outside the independent claims if they affect the non-negotiable thresholds.
Key Takeaways
- US 8,334,281 claim scope is defined by stability-driven composition constraints: intranasal metoclopramide + citrate concentration >= 10 mM + benzalkonium chloride, with clarity vs USP <631> standard E after 40°C for 4+ weeks.
- Claim 17 adds a benzyl alcohol cap (<1% w/v) and preserves the same citrate and USP <631> clarity anchors.
- Major design-risk parameters include: BAK at 0.005–0.05% w/v, metoclopramide at 20–30% w/v, osmolality 500–1400 mOsm/kg, and starting pH >=4.5 (with higher thresholds in dependent claims).
- Method coverage covers intranasal administration for metoclopramide-treatable indications: gastroparesis, emesis, delayed emesis, nausea.
- Landscape implication at the technical level: the competitive field is segmented by whether products meet the USP <631> appearance stability target and whether they keep citrate >=10 mM while using BAK.
FAQs
1) Is the patent limited to citrate-only buffers?
The independent claim text requires a citrate buffer and defines citrate concentration as >=10 mM. Dependent Claim 13 lists many buffers, but it is still dependent on the Claim 1 framework that includes citrate concentration and citrate buffer requirements.
2) What does “clear to pale yellow when compared to standard E USP <631>” do to the scope?
It introduces a finished-product stability/appearance requirement after accelerated storage (40°C), making compliance depend on formulation chemistry and how it evolves under stress, not only on initial composition.
3) Where is benzalkonium chloride positioned in the claim set?
BAK is a required component in the independent composition claims, and dependent claims add a quantitative range of 0.005–0.05% w/v.
4) Does the patent require benzyl alcohol absence?
No. Claim 1 does not mention benzyl alcohol. Claim 17 requires less than about 1% w/v benzyl alcohol, so benzyl alcohol presence can still be compatible with Claim 17 if it stays below that threshold.
5) Which clinical indications are covered by the method claims?
The method claims explicitly list: gastroparesis, emesis, delayed emesis, nausea.
References
[1] US Patent 8,334,281, “Metoclopramide nasal solution with citrate buffer and benzalkonium chloride” (claims provided in prompt).
